Document:

Exhibit 4.1 

 

THE
SECURITIES REPRESENTED HEREBY AND THE SECURITIES ISSUABLE UPON CONVERSION THEREOF HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE
UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “1933 ACT”), OR THE LAWS OF ANY STATE OF THE UNITED STATES. THE HOLDER
HEREOF, BY PURCHASING SUCH SECURITIES, AGREES FOR THE BENEFIT OF THE COMPANY THAT SUCH SECURITIES MAY BE OFFERED, SOLD, PLEDGED OR OTHERWISE
TRANSFERRED ONLY (A) TO THE COMPANY, (B) OUTSIDE THE UNITED STATES IN ACCORDANCE WITH RULE 904 OF REGULATION S UNDER THE 1933 ACT AND
IN COMPLIANCE WITH APPLICABLE LOCAL LAWS AND REGULATIONS, (C) IN COMPLIANCE WITH THE EXEMPTION FROM REGISTRATION UNDER THE 1933 ACT PROVIDED
BY RULE 144 THEREUNDER, IF AVAILABLE, AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS OR (D) IN ANOTHER TRANSACTION THAT DOES
NOT REQUIRE REGISTRATION UNDER THE 1933 ACT OR ANY APPLICABLE STATE SECURITIES LAWS AND, IN THE CASE OF (C) AND (D) ABOVE, AFTER THE
SELLER FURNISHES TO THE COMPANY AN OPINION OF COUNSEL OF RECOGNIZED STANDING OR OTHER EVIDENCE IN FORM AND SUBSTANCE SATISFACTORY TO
THE COMPANY TO SUCH EFFECT. 

 

THE
PRESENCE OF THIS LEGEND MAY IMPAIR THE ABILITY OF THE HOLDER HEREOF TO EFFECT “GOOD DELIVERY” OF THE SECURITIES REPRESENTED
HEREBY ON A CANADIAN STOCK EXCHANGE.

 

PROMIS
NEUROSCIENCES INC.

AMENDED AND RESTATED

UNSECURED CONVERTIBLE
DEBENTURE DUE MARCH 22, 2026

  

DEBENTURE

	CERTIFICATE NUMBER: [NO. 2021-CD-l]	PRINCIPAL AMOUNT: $[l]

 

 

 

PROMIS NEUROSCIENCES
INC. (the “Company”), a company incorporated under the Canada Business Corporations Act, issued the Unsecured
Convertible Debenture (the “Original Debenture”) due March 22, 2026 registered in the name of [l-
Name of Holder at Address of Holder] (the “Holder”) on March 22, 2021 (the “Issue Date”). This
Amended and Restated Unsecured Convertible Debenture (the “Debenture”) due March 22, 2026 (the “Maturity
Date”) amends and restates the terms of the Original Debenture.

 

All capitalized
terms not otherwise defined in this Debenture have the meanings attributed to them in Schedule “A”.

 

The Company, for
value received, hereby acknowledges itself indebted and promises to pay to the Holder on the Maturity Date or on such earlier date as
the Principal Amount hereof may become due in accordance with the provisions hereof, the Principal Amount of $[l]
on presentation and surrender of this Debenture at the head office of the Company at Suite 200, 1920 Yonge Street, Toronto, Ontario M4S
3E2, Attention: CFO, or such other office as the Company may advise the Holder in writing.

 

Subject to the
terms set forth herein including, without limitation, the right of the Company to convert the Debenture into common shares of the Company
(the “Common Shares”) at the Conversion Price and in certain circumstances as more particularly described herein,
the Holder has the right, from time to time and at any time on or prior to 5:00 p.m. (Vancouver time) on the Business Day immediately
preceding the Maturity Date, to convert all or any portion of the outstanding Principal Amount into series 1 preferred shares of the
Company (the “Series 1 Shares”) at the Conversion Price with respect to the Principal Amount, equal to US$0.10 per
Series 1 Share, provided no partial conversion shall be for less than the Minimum Threshold Amount. On conversion, the Holder will receive
any accrued and unpaid interest in cash. For the avoidance of doubt, although the Company may elect to convert the Debentures into Common
Shares or Series 1 Shares in certain circumstances, the Holder may only convert the Debenture into Series 1 Shares.

 

     

    - 2 -

    

  

Except upon the
occurrence of an Event of Default after which the following transfer restriction will no longer apply, this Debenture shall be non-transferrable,
in whole or in part, to anyone without the express prior written consent of the Company. For the purposes of this Debenture, a “transfer”
includes any sale, exchange, transfer, assignment, gift, pledge, encumbrance, hypothecation, alienation or other transaction, whether
voluntary, involuntary or by operation of law, whether in whole or in part, by which the legal or beneficial ownership of, or any security
interest or other interest in the Debenture, passes from one person to another, indirectly or directly, or to the same person in a different
capacity, whether or not for value. Notwithstanding the foregoing, the Holder may transfer the Debenture without the prior express written
consent of the Company to: (i) the spouse of the Holder; or (ii) a corporation of which the Holder or the spouse of the Holder is/are
the sole registered and beneficial shareholder(s).

 

This Debenture
is issued subject to the terms and conditions appended hereto as Schedule “A”.

 

IN WITNESS WHEREOF,
the Company has caused this Debenture to be executed by a duly authorized officer.

 

DATED for reference
this ____ day of June, 2022.

 

	 	PROMIS NEUROSCIENCES
    INC.
	 	 
	 	Per:	 
	 	 	Name:
	 	 	Title: 

  

(See terms and
conditions attached hereto)

  

     

     

    

  

SCHEDULE
 “A”

 

TERMS
AND CONDITIONS FOR DEBENTURE

 

Article 1

INTERPRETATION

 

		1.1	Defined
                                            Terms

 

In
this Debenture, unless there is something in the subject matter or context inconsistent therewith, the following words and terms shall
have the meanings set out below:

 

		(a)	“1933
                                            Act” means the United States Securities Act of 1933, as amended;

 

		(b)	“Applicable
                                            Securities Laws” any and all securities laws including, statutes, rules, regulations,
                                            by-laws, policies, guidelines, orders, decisions, rulings and awards, applicable in the jurisdiction
                                            in which the Debenture will be offered, sold and issued or where the Company carries on business;

 

		(c)	“Business
                                            Day” means a day, other than a Saturday, Sunday or statutory or civic holiday in
                                            the City of Toronto, Ontario;

 

		(d)	“Capital
                                            Reorganization” has the meaning set forth in Section 4.3(a);

 

		(e)	“Common
                                            Shares” means fully-paid and non-assessable common shares in the capital of the
                                            Company;

 

		(f)	“Company”
                                            means ProMIS Neurosciences Inc. and its successors and assigns;

 

		(g)	“Conversion
                                            Date” means the date on which a notice of conversion is received by the Company
                                            pursuant to Section 4.2(a);

 

		(h)	“Conversion
                                            Price” means, subject to Section 4.3, US$0.10 per Series 1 Preferred Share
                                            or US$0.10 per Common Share, as the context requires;

 

		(i)	“Conversion
                                            Rights” means the rights of the Holder to convert the Debenture into Series 1 Shares
                                            pursuant to Article 4;

 

		(j)	“Convertible
                                            Securities” shall have the meaning set forth in Section 2.7(a);

 

		(k)	“Cure
                                            Period” shall have the meaning set forth in Section 6.1;

 

		(l)	“Current
                                            Market Price” shall have the meaning set forth in Section 4.3(c);

 

		(m)	“Debenture”
                                            means this Debenture as supplemented, amended or otherwise modified, renewed or replaced
                                            from time to time;

 

		(n)	“Holder”
                                            shall have the meaning set forth on the cover page of this Debenture;

 

		(o)	“Distributed
                                            Securities” shall have the meaning set forth in Section 2.7(a);

 

		(p)	“Distribution”
                                            shall have the meaning set forth in Section 2.7(a);

 

		(q)	“Events
                                            of Default” shall have the meaning set forth in Section 5.1;

 

     

    A-2 

    

  

		(r)	“Exempt
                                            Issuances” means (i) securities issued upon the conversion or exercise of any debenture,
                                            warrant, option or other convertible security existing as of the Issue Date, (ii) Common
                                            Shares issuable upon a share split, share dividend or similar transaction, (iii) Common Shares
                                            (or options to purchase Common Shares) issued or issuable to employees, officers, directors
                                            or consultants of the Company pursuant to any stock option plan or other long term incentive
                                            plan approved by the board of directors of the Company, and (iv) the issuance of securities
                                            in connection with acquisition transactions, as approved by the board of directors of the
                                            Company;

 

		(s)	“Forced
                                            Conversion Notice” shall have the meaning set forth in Section 4.8;

 

		(t)	“Forced
                                            Conversion Shares” shall have the meaning set forth in Section 4.8;

 

		(u)	“Forced
                                            Conversion Trigger” shall have the meaning set forth in Section 4.8;

 

		(v)	“Interest
                                            Due Date” shall have the meaning set forth in Section 2.2;

 

		(w)	“Issue
                                            Price” shall have the meaning set forth in Section 2.7(b);

 

		(x)	“Market
                                            Price” means the five (5) day volume weighted average trading price of the Common
                                            Shares determined by dividing the total value by total volume of the Common Shares traded
                                            on the TSX for the five (5) trading days immediately prior to the relevant date;

 

		(y)	“Maturity
                                            Date” mean March 22, 2026;

 

		(z)	“Minimum
                                            Threshold Amount” means the minimum Principal Amount of this Debenture that may
                                            be partially converted or redeemed, as applicable, such amount being US$100,000;

 

		(aa)	“Official
                                            Body” means any government or political subdivision or any agency, authority, bureau,
                                            central bank, monetary authority, commission, department or instrumentality thereof, or any
                                            court, tribunal or arbitrator, whether foreign or domestic;

 

		(bb)	“person”
                                            means an individual, partnership, corporation, trust, unincorporated association, joint venture
                                            or government or any agent, instrument or political subdivision thereof;

 

		(cc)	“Pre-emptive
                                            Notice” shall have the meaning set forth in Section 2.7(c);

 

		(dd)	“Pre-emptive
                                            Right” shall have the meaning set forth in Section 2.7(a);

 

		(ee)	“Principal
                                            Amount” means the principal amount outstanding under this Debenture from time to
                                            time;

 

		(ff)	“Receiver”
                                            means any receiver or receiver-manager of the Company;

 

		(gg)	“Reclassification
                                            of Common Shares” shall have the meaning set forth in Section 4.3(d);

 

		(hh)	“Redemption
                                            Date” shall have the meaning set forth in Section 2.5;

 

		(ii)	“Redemption
                                            Notice” shall have the meaning set forth in Section 2.5;

 

		(jj)	“Series
                                            1 Shares” means series 1 preferred shares in the capital of the Company as constituted
                                            on the date hereof which the Holder is entitled to receive upon the conversion of the Debenture
                                            pursuant to Article 4, and after the date hereof, such series 1 preferred shares in
                                            the capital of the Company or any other shares, securities, money or property, which the
                                            Holder is entitled to receive in respect or substitution of such series 1 preferred shares,
                                            upon conversion of the Debenture pursuant to Article 4;

 

     

    A-3 

    

  

		(kk)	“Special
                                            Distribution” shall have the meaning set forth in Section 4.3(b);

 

		(ll)	“Subscription
                                            Securities” shall have the meaning set forth in Section 2.7(b);

 

		(mm)	“TSX”
                                            means the Toronto Stock Exchange or, if the Common Shares are listed or posted for trading
                                            on any other stock exchange or over-the-counter market, then such other exchange or market
                                            if the Common Shares are not at the applicable time listed on the TSX;

 

		(nn)	“United
                                            States” or “U.S.” means, as the context requires, the United
                                            States of America, its territories and possessions, any state of the United States and/or
                                            the District of Columbia; and

 

		(oo)	“U.S.
                                            person” has the meaning ascribed to that term in Rule 902(k) of Regulation S under
                                            the 1933 Act.

 

		1.2	Currency

 

All
references to dollar amounts herein are references to currency of the United States.

 

Article 2

DEBENTURE

 

		2.1	Principal
                                            Amount

 

The
Company agrees to repay to the Holder the Principal Amount of the Debenture, together with interest thereon, by 5:00 p.m. (Vancouver
time) on the Maturity Date, subject to the right to convert the Debenture pursuant to Section 4.1 or Section 4.7 and the Company’s
right to redeem the Principal Amount in Common Shares and interest thereon in cash pursuant to Section 2.4.

 

		2.2	Interest
                                            on Debenture

 

Interest
shall accrue on the Principal Amount of the Debenture, from day to day, before as well as after maturity, before as well as after default
and before as well as after judgement, at a rate of 1.0% per annum, calculated and payable annually in arrears, commencing on March 22,
2022 and every anniversary thereafter (each, an “Interest Due Date”) until the Maturity Date. Accrued interest payable
on an Interest Due Date or the Maturity Date will be satisfied in cash.

 

If
the Company fails to make the payment of Principal Amount or interest required to be made hereunder, on the day on which the same is
due and payable, the Company will pay interest on the amount or amounts so required to have been paid at the rate of interest as aforesaid
calculated and payable from the date of such failure until the date of payment.

 

		2.3	Interest
                                            on Redemption or Conversion

 

Upon
redemption or conversion of all or part of the Principal Amount of the Debenture, any accrued and unpaid interest in respect of such
redeemed or converted Principal Amount will be paid in cash.

 

		2.4	Redemption
                                            of Debenture in Common Shares

 

Subject
to receipt of approval of the TSX (and, if applicable, holders of Common Shares), the Company may redeem all or a portion of the Principal
Amount plus any accrued and unpaid interest, if applicable, on the Maturity date, by issuing Common Shares in lieu of cash with respect
to the principal and cash with respect to any accrued and unpaid interest, provided that the Company provides notice to the Holder pursuant
to Section 2.5. The number of Common Shares to be issued pursuant to any such redemption shall be calculated by dividing the redemption
amount by the greater of: (i) the Market Price as of the date of the Redemption Notice less a 10% discount, and (ii) the minimum price
permitted by the rules of the TSX.

 

		2.5	Notice
                                            of Redemption

 

The
Company will give notice of redemption (the “Redemption Notice”), in accordance with Section 7.3 hereof, to the
Holder not less than fourteen (14) Business Days but not more than thirty (30) Business Days prior to the date of redemption (the “Redemption
Date”). The Redemption Notice shall specify the aggregate Principal Amount of the Debenture to be redeemed, the accrued and
unpaid interest in respect of such redeemed Principal Amount and whether the Company will redeem all or a part of the Principal Amount
in cash or Common Shares. Upon receiving a Redemption Notice whereby the Company is electing to redeem all or part of the Principal Amount,
the Holder will be entitled (on written notice being given by the Holder to the Company at least one (1) Business Day before the Redemption
Date) to convert the Principal Amount called for redemption at the Conversion Price pursuant to Article 4 at any time prior to the
Redemption Date.

 

     

    A-4 

    

  

		2.6	Payment
                                            of Amount Redeemed

 

Upon
a Redemption Notice being given, that portion of the Debenture that is being redeemed will become due and payable on the Redemption Date
specified in the Redemption Notice and the Company may not withdraw the Redemption Notice without the prior consent of the Holder.

 

		2.7	Pre-emptive
                                            Right

 

		(a)	Subject
                                            to any required approval by, or notice to, the TSX under the rules and regulations of the
                                            TSX (and where applicable, any required shareholder approval), in the event of any private
                                            placement (i.e., a capital raising, prospectus-exempt offering) or public offering (i.e.,
                                            a capital raising, prospectus offering) from and after the Issue Date (in each case, a “Distribution”),
                                            other than, for greater certainty, Exempt Issuances, of Common Shares or of securities convertible
                                            or exchangeable into Common Shares or otherwise presenting a right to acquire Common Shares
                                            (“Convertible Securities” and, together with the Common Shares, the “Distributed
                                            Securities”), the Holder shall have the right (the “Pre-emptive Right”)
                                            to subscribe for that number of Common Shares or Convertible Securities, as the case may
                                            be, on the same terms and conditions, including subscription or exercise price, as applicable,
                                            sufficient for the Holder to maintain the same percentage ownership in the Common Shares
                                            (on an as-converted basis, as the case may be) as the Holder had immediately prior to the
                                            Distribution, on a fully diluted basis.

 

		(b)	To
                                            the extent that any Pre-emptive Right is exercised, in whole or in part, the securities underlying
                                            such Pre-emptive Right (the “Subscription Securities”) shall be issued
                                            and must be paid for concurrently with the completion of the Distribution and payment to
                                            the Company of the issue price for the Distributed Securities, at the price (the “Issue
                                            Price”) at which the Distributed Securities are then being issued or distributed.

 

		(c)	At
                                            least seven (7) Business Days prior to the closing of any proposed Distribution, the Company
                                            shall deliver to the Holder a notice (the “Pre-emptive Notice”) in writing
                                            offering the Holder the opportunity to subscribe for the applicable number of Subscription
                                            Securities. The Pre-emptive Notice will contain a description of the terms and conditions
                                            relating to the Distributed Securities and will, to the extent known, state the Issue Price
                                            at which the Distributed Securities will be distributed and the date on which the issuance
                                            of Distributed Securities is to be completed. If the Holder wishes to subscribe for Subscription
                                            Securities, the Holder may do so only by giving written notice of the exercise of the Pre-emptive
                                            Right within five (5) Business Days after the date of the Pre-emptive Notice.

 

Article 3

COVENANTS

 

		3.1	Covenants
                                            of the Company

 

The
Company covenants and agrees with the Holder that, unless otherwise consented to in writing by the Holder:

 

		(a)	Observe
                                            Obligations. The Company will duly pay or cause to be paid to the Holder the Principal
                                            Amount and interest of this Debenture and any other amounts owed to the Holder at the dates
                                            and places, and in the manner set forth herein;

 

     

    A-5 

    

  

		(b)	Reservation
                                            of Series 1 Shares and Common Shares. The Company shall at all times have reserved for
                                            issuance out of its authorized capital a sufficient number of Series 1 Shares to satisfy
                                            its obligations to issue and deliver Series 1 Shares upon the due conversion of the Debenture.
                                            The Company shall at all times have reserved for issuance out of its authorized capital a
                                            sufficient number of Common Shares issuable upon conversion or redemption, as applicable,
                                            of the Debenture or the Series 1 Shares into Common Shares, and in the case of the Series
                                            1 Shares, in accordance with the terms of the Series 1 Shares.

 

		(c)	Approvals
                                            and Filings. The Company shall, in connection with the execution and delivery of this
                                            Debenture, the conversion of the Debenture into Common Shares or Series 1 Shares, as applicable,
                                            obtain any and all requisite approvals of the holders of Common Shares and statutory and
                                            regulatory approvals required to effect and complete the same and shall file all notices,
                                            reports and other documents required to be filed by or on behalf of the Company pursuant
                                            to Applicable Securities Laws in respect thereof, including the rules and regulations of
                                            the TSX;

 

		(d)	Restrictions
                                            in the U.S. This Debenture and the securities deliverable upon conversion hereof have
                                            not been and will not be registered under the 1933 Act, or the securities laws of any state
                                            of the United States. This Debenture may not be converted in the United States, or by or
                                            for the account or benefit of a U.S. person or a person in the United States, unless (i)
                                            the underlying Common Shares and Series 1 Shares, as applicable, are registered under the
                                            1933 Act and the applicable laws of any U.S. state, or (ii) an exemption from such registration
                                            requirements is available, and (iii) the Holder has complied with the requirements set forth
                                            in the Conversion Form attached hereto as Schedule “B”;

 

		(e)	Listing.
                                            The Company shall at all times while this Debenture is outstanding, use its best efforts
                                            to maintain its status as a “reporting issuer” not in default in all of the Provinces
                                            and Territories of Canada other than Quebec and the listing of the Common Shares on the TSX.
                                            In addition, the Company shall use commercially reasonable efforts to list the Common Shares
                                            on the Nasdaq, if the board of directors of the Company determines that it would be in the
                                            best interest of the Company to seek such listing;

 

		(f)	Canadian
                                            Securities Laws. All Common Shares or Series 1 Shares issued to the Holder upon conversion
                                            of the Debenture or any part thereof shall be made pursuant to an exemption from prospectus
                                            and registration requirements available to the Holder or the Company in respect of the transactions
                                            contemplated herein under Applicable Securities Laws; and

 

		(g)	Holder
                                            Approval. The Company shall not issue any convertible debt ranking senior to the Debentures
                                            without the written consent of holders of at least 60% of the then outstanding Debentures
                                            unless: (i) more than 50% of the Debentures have been converted or redeemed, (ii) the Market
                                            Price of the Common Shares at the time of issuance of such convertible debt is greater than
                                            two times the Conversion Price, or (iii) such convertible debt is issued on or after March
                                            22, 2025.

 

Article 4

CONVERSION Of principal amount

 

		4.1	Conversion
                                            Privilege and Conversion Price

 

		(a)	The
                                            Holder shall have the right, from time to time and at any time following the Issue Date and
                                            at any time on or prior to 5:00 p.m. (Vancouver time) on the Business Day immediately preceding
                                            the Maturity Date, to convert to Series 1 Shares (unless converted into Common Shares at
                                            the discretion of the Company under certain circumstances), all or any part of the outstanding
                                            Principal Amount of the Debenture on the Conversion Date, at the Conversion Price, provided
                                            no partial conversion shall be for less than the Minimum Threshold Amount.

 

		(b)	In
                                            the event the Holder receives a Redemption Notice from the Company in accordance with Section 2.5
                                            hereof, the Holder shall have the right to convert to Series 1 Shares (unless converted into
                                            Common Shares at the discretion of the Company under certain circumstances) all or any part
                                            of the outstanding Principal Amount of the Debenture on the Conversion Date at the Conversion
                                            Price, subject to the Holder having provided the Company, at least one (1) Business Day prior
                                            to the Redemption Date, with notice of such election in accordance with Section 4.2
                                            below.

 

     

    A-6 

    

 

		4.2	Manner
                                            of Exercise of Right to Convert or Purchase

 

		(a)	The
                                            Holder may, at any time commencing following the Issue Date and at any time on or prior to
                                            5:00 p.m. (Vancouver time) on the Business Day immediately preceding the Maturity Date, convert
                                            the outstanding Principal Amount of the Debenture on the Conversion Date, in whole or in
                                            part, provided that no conversion shall be for less than the Minimum Threshold Amount, into
                                            Series 1 Shares (unless converted into Common Shares at the discretion of the Company under
                                            certain circumstances) at the Conversion Price, by delivering to the Company, the conversion
                                            form attached hereto as Schedule B executed by the Holder or the Holder’s attorney
                                            duly appointed by an instrument in writing, exercising the Holder’s right to convert
                                            the Debenture in accordance with the provisions of this Article 4. Thereupon, the Holder
                                            or, subject to payment of all applicable stamp or security transfer taxes or other governmental
                                            charges, the Holder’s nominee(s) or assignee(s) shall be entitled to be entered in
                                            the books of the Company as at the Conversion Date (or such later date as is specified in
                                            Section 4.2(b) as the holder of the number of Series 1 Shares into which the Debenture is
                                            convertible in accordance with the conversion form then received by the Company and the provisions
                                            of this Article 4 and, as soon as practicable thereafter, the Company shall deliver
                                            to the Holder and/or, subject as aforesaid, the Holder’s nominee(s) or assignee(s),
                                            a certificate or certificates for such Series 1 Shares affixed with all required legends;

 

		(b)	For
                                            the purposes of this Article 4, the Debenture shall be deemed to be converted on the
                                            Conversion Date on which the conversion form under Section 4.2(a) is actually received by
                                            the Company, provided that if such conversion form or notice is received on a day on which
                                            the register of Series 1 Shares is closed, the person or persons entitled to receive Series
                                            1 Shares shall become the holder or holders of record of such Series 1 Shares as at the date
                                            on which such register is next reopened;

 

		(c)	Any
                                            part of the Principal Amount of the Debenture may be converted as provided in Section 4.2(a)
                                            and if this Debenture is tendered for partial conversion, the Debenture shall be cancelled
                                            as to the Principal Amount thereunder that is being converted and the Debenture shall be
                                            deemed to be in the amount of the remaining Principal Amount; and

 

		(d)	The
                                            Holder shall be entitled in respect of Series 1 Shares issued upon conversion of the Debenture
                                            to dividends declared in favour of holders of Common Shares of record on and after the Conversion
                                            Date or such later date as the Holder shall become the holder of record of such Series 1
                                            Shares pursuant to Section 4.2(b), from which applicable date any Series 1 Shares so issued
                                            to the Holder shall for all purposes be and be deemed to be outstanding as fully paid and
                                            non-assessable.

 

		4.3	Adjustment
                                            of Conversion Price When Converting into Common Shares

 

The
Conversion Price into Common Shares in effect at any date shall be subject to adjustment from time to time as follows:

 

		(a)	If
                                            and whenever at any time prior to the close of business of the Company up to and including
                                            the Maturity Date, (referred to in this Section 4.3 as the “Time of Expiry”),
                                            the Company shall:

 

		(i)	subdivide,
                                            redivide or change its Common Shares into a greater number of shares;

 

		(ii)	consolidate,
                                            reduce or combine its Common Shares into a lesser number of shares; or

 

		(iii)	issue
                                            Common Shares to all or substantially all of the holders of its Common Shares by way of a
                                            stock dividend or other distribution on such Common Shares payable in Common Shares (other
                                            than dividends paid in the ordinary course),

 

(any
such event being hereinafter referred to as a “Capital Reorganization”), the Conversion Price shall be adjusted by
multiplying the Conversion Price in effect on the effective date of such event referred to in Section 4.3(a)(i) or Section 4.3(a)(ii)
or on the record date of such stock dividend referred to in Section 4.3(a)(iii), as the case may be, by a fraction, the numerator of
which shall be the number of Common Shares outstanding before giving effect to such Capital Reorganization and the denominator of which
shall be the number of Common Shares outstanding after giving effect to such Capital Reorganization. Such adjustment shall be made successively
whenever any Capital Reorganization shall occur and any such issue of Common Shares by way of a stock dividend or other such distribution
shall be deemed to have been made on the record date thereof for the purpose of calculating the number of outstanding Common Shares under
Sections 4.3(a)(i) and 4.3(a)(ii);

 

     

    A-7 

    

 

 

		(b)	If
                                            and whenever at any time prior to the Time of Expiry, the Company shall fix a record date
                                            for the distribution to all or substantially all the holders of its Common Shares of:

 

		(i)	shares
                                            of any class whether of the Company or any other corporation (excluding dividends paid in
                                            the ordinary course);

 

		(ii)	rights
                                            or options;

 

		(iii)	evidences
                                            of indebtedness; or

 

		(iv)	other
                                            assets or property (excluding dividends paid in the ordinary course),

 

and if
such distribution does not constitute a Capital Reorganization or does not consist of rights or options entitling the holders, for a
period expiring not more than forty-five (45) days after such record date, to subscribe for or purchase Common Shares at a price per
share or having a conversion or exchange price per share of at least 95% of the Current Market Price per Common Share on such record
date (any such non-excluded event being hereinafter referred to as a “Special Distribution”), the Conversion Price
shall be adjusted immediately after such record date so that it shall equal the price determined by multiplying the Conversion Price
in effect on such record date by a fraction, of which the numerator shall be the total number of Common Shares outstanding on such record
date multiplied by the Current Market Price per Common Share determined on such record date, less the excess of the fair market value
(as determined by the board of directors of the Company, which determination shall be conclusive and subject to TSX acceptance) of such
Special Distribution over the fair market value (as determined by the board of directors of the Company, which determination shall be
conclusive and subject to TSX acceptance) of the consideration therefor, if any, received by the Company and of which the denominator
shall be the total number of Common Shares outstanding on such record date multiplied by such Current Market Price per Common Share.
Any Common Shares owned by or held for the account of the Company shall be deemed not to be outstanding for the purposes of any such
computation. Such adjustment shall be made successively whenever such a record date is fixed. The extent that such Special Distribution
is not so made or to the extent any such rights, options are not exercised prior to the expiration thereof, the Conversion Price shall
then be readjusted to the Conversion Price which would then be in effect if such record date had not been fixed or if such expired rights
or options had not been issued;

 

		(c)	For
                                            the purpose of any computation under Section 4.3(b), the “Current Market Price”
                                            per Common Share at any date shall be the Market Price per share of such Common Shares on
                                            the TSX ending three Business Days immediately preceding such date, or, if the Common Shares
                                            are not listed on the TSX, any other exchange on which the Common Shares are listed or, if
                                            the Common Shares are not listed on any exchange, on any over-the-counter market on which
                                            the Common Shares are quoted;

 

		(d)	If
                                            and whenever at any time prior to the Time of Expiry, there is a reclassification or change
                                            of Common Shares into other shares or there is a consolidation, merger, reorganization or
                                            amalgamation of the Company with or into another corporation or entity that results in any
                                            reclassification of Common Shares or a change of Common Shares into other shares or there
                                            is a transfer of the undertaking or assets of the Company as an entirety or substantially
                                            as an entirety to another person (any such event being hereinafter referred to as a “Reclassification
                                            of Common Shares”), the Holder shall be entitled to receive and shall accept, upon
                                            the exercise of the Holder’s right of conversion at any time after the effective date
                                            thereof, in lieu of the number of Common Shares to which the Holder was theretofore entitled
                                            on conversion, the kind and amount of shares or other securities or money or other property
                                            that the Holder would have been entitled to receive as a result of such Reclassification
                                            of Common Shares, if, on the effective date thereof, the Holder had been the registered holder
                                            of the number of such Common Shares to which the Holder was theretofore entitled upon conversion,
                                            subject to adjustment thereafter in accordance with provisions the same, as nearly as may
                                            be possible, as those contained in this Section 4.3;

 

     

    A-8 

    

 

 

		(e)	In
                                            any case in which this Section 4.3 shall require that an adjustment become effective
                                            immediately after a record date or agreement date for an event referred to herein, the Company
                                            may defer, until the occurrence of such event, issuing or transferring to the Holder who
                                            converts on a Conversion Date after such record date or agreement date and before the occurrence
                                            of such event the additional Common Shares issuable upon conversion by reason of the adjustment
                                            of the Conversion Price required by such event before giving effect to such adjustment; provided,
                                            however, that the Company shall deliver to the Holder an appropriate instrument evidencing
                                            the Holder's right to receive such additional Common Shares upon the occurrence of the event
                                            requiring such adjustment and the right to receive any distributions made on such additional
                                            Common Shares on and after the Conversion Date or such later date as the Holder would, but
                                            for the provisions of this Section 4.3(e), have become the holder of record of such additional
                                            Common Shares pursuant to Section 4.3(b);

 

		(f)	In
                                            case the Company after the date hereof shall take any action affecting its Common Shares,
                                            other than any action described in this Section 4.3, which in the opinion of the Holder,
                                            acting reasonably, would materially affect the conversion rights of the Holder, the Conversion
                                            Price shall be adjusted in such manner, at such time and by such action by the board of directors
                                            of the Company, as they may determine, acting reasonably, to be equitable to the Holder and
                                            the Company in the circumstances, but subject in all cases to any necessary regulatory approval;

 

		(g)	The
                                            adjustments provided for in this Section 4.3 are cumulative and shall apply to successive
                                            subdivisions, redivisions, reductions, combinations, consolidations, distributions, issues
                                            or other events resulting in any adjustment under the provisions of this Section, provided
                                            that, notwithstanding any other provision of this Section, no adjustment shall be made which
                                            would result in any increase in the Conversion Price (except upon a consolidation, reduction
                                            or combination of outstanding Common Shares) and no adjustment of the Conversion Price shall
                                            be required unless such adjustment would require a decrease of at least 1% in the Conversion
                                            Price then in effect; provided, however, that any adjustments which by reason of this subsection
                                            (h) are not required to be made shall be carried forward and taken into account in any subsequent
                                            adjustment;

 

		(h)	In
                                            the event of any dispute arising with respect to the adjustments provided in this Section 4.3,
                                            such question shall be conclusively determined by a firm of chartered professional accountants
                                            appointed by the Company (who may be auditors of the Company) and acceptable to the Holder.
                                            Such accountants shall have access to all necessary records of the Company and such determination
                                            shall be binding upon the Company and the Holder;

 

		(i)	Notwithstanding
                                            any other provision herein contained, no adjustment to the Conversion Price shall be made
                                            in respect of any event described in this Section 4.3, if the Holder is entitled, without
                                            converting the Debenture, to participate in such event, subject to TSX acceptance, on the
                                            same terms mutatis mutandis as if the Holder had converted the Debenture into Common Shares
                                            prior to or on the effective date or record date of such event; and

 

		(j)	If
                                            any Series 1 Shares or Common Shares to be issued upon the conversion of the Debenture hereunder
                                            require any filing or registration with or approval of any Official Body in Canada or the
                                            United States or compliance with any other requirement under any law of Canada or the United
                                            States or province or state thereof before such shares may be validly issued upon such conversion
                                            or traded by the person to whom they are issued pursuant to such conversion, the Company
                                            will take all reasonable action as may be necessary to secure such filing, registration,
                                            approval or compliance as the case may be.

 

		4.4	Adjustment
                                            of Conversion Price When Converting into Series 1 Shares

 

The
Conversion Price into Series 1 Shares in effect at any date shall be subject to adjustment from time to time in accordance with Section 4.3
as if the Series 1 Shares were Common Shares for the purposes of all calculations undertaken under Section 4.3 to affect the relevant
adjustment.

 

		4.5	No
                                            Requirement to Issue Fractional Shares

 

The
Company shall not be required to issue fractional Common Shares or Series 1 Shares, as applicable, upon the conversion of the Debenture
pursuant to this Article 4 or at the discretion of the Company.

     

    A-9 

    

 

 

 

		4.6	Certificate
                                            as to Adjustment

 

The
Company shall from time to time forthwith after the occurrence of any event which requires adjustment or readjustment as provided in
Section 4.3, deliver to the Holder at the Holder’s address set forth on the final page hereof, an officer's certificate specifying
the nature of the event requiring the same and the amount of the adjustment necessitated thereby and setting forth in reasonable detail
the method of calculation and the facts upon which such calculation are based.

 

		4.7	Limits
                                            on Conversion

 

		(a)	Subject to Section
                                            4.7(b), at any given time during the term of this Debenture until the Maturity Date, the
                                            Holder may only convert such amount of the Principal Amount that, upon issuance of the Common
                                            Shares or Series 1 Shares issuable upon conversion thereof, together with any other Common
                                            Shares and securities convertible or exercisable into Common Shares, including the Series
                                            1 Preferred Shares, calculated on an “as if converted” and “as if exercised
                                            basis”, that are beneficially owned or controlled or directed by the Holder, will result
                                            in the Holder owning, or having control or direction over, less than 10% of the issued and
                                            outstanding Common Shares. For greater clarity, the Holder may not convert any portion of
                                            the Principal Amount if the Common Shares or Series 1 Shares issued upon the conversion thereof
                                            together with any other securities beneficially owned or controlled or directed by the Holder
                                            will result in the Holder owning or having control or direction over or being deemed to own
                                            or have control or direction over 10% or more of the Company’s issued and outstanding
                                            Common Shares such that the Holder will become a reporting insider under Applicable Securities
                                            Laws by virtue of such conversion.

 

		(b)	Section 4.6(a)
                                            shall not apply to the Holder provided that the Holder gives no less than sixty-one (61)
                                            days notice to the Company.

 

		4.8	Forced
                                            Conversion

 

Provided
there is no Event of Default as contemplated herein, if at any time after June 30, 2022 until the Maturity Date, the Company raises gross
proceeds of US$30,000,000 from the sale of equity securities or securities convertible into equity securities (the “Forced Conversion
Trigger”), the Company may upon not less than five (5) Business Days’ and not more than twenty (20) Business Days’
prior written notice to the Holder (the “Forced Conversion Notice”), require the conversion of all or part of the
Principal Amount into Common Shares at the Conversion Price (the “Forced Conversion Shares”). Any accrued and unpaid
interest in respect of such converted Principal Amount will be paid in cash. The Company shall issue and deliver to the Holder a share
certificate representing the Forced Conversion Shares and cash representing accrued interest within five (5) Business Days of the date
of conversion specified in any Forced Conversion Notice, which conversion date shall be no later than five (5) Business Days after the
closing date of the applicable financing.

 

Article 5

EVENTS OF DEFAULT

 

		5.1	General

 

The
occurrence of any one or more of the following events (“Events of Default”) will constitute a default hereunder (whether
any such event is voluntary or involuntary or is effected by operation of law or pursuant to or in compliance with any judgment, decree
or order of any court of any order, rule or regulation of any administrative or governmental body):

 

		(a)	Non-Compliance.
                                            The Company fails to observe or perform one or more covenants, agreements, conditions
                                            or obligations in favour of the Holder, including a failure to pay any or all of the Principal
                                            Amount, interest and other monies due under the Debenture when due, and such failure continues
                                            unremedied for a period of fifteen (15) days after the Holder gives notice thereof to the
                                            Company;

 

		(b)	Ceasing to
                                            Carry on Business. The Company ceases or threatens to cease to carry on business;

 

     

    A-10 

    

 

		(c)	Bankruptcy
                                            or Insolvency. The Company becomes insolvent or makes a voluntary assignment or proposal
                                            in bankruptcy or otherwise acknowledges its insolvency, or a bankruptcy petition is filed
                                            or presented against the Company, or the Company commits or threatens to commit an act of
                                            bankruptcy;

 

		(d)	Receivership.
                                            A Receiver of the Company or its subsidiary is appointed under any statute or pursuant
                                            to any document issued by the Company;

 

		(e)	Compromise
                                            or Arrangement. Any proceedings with respect the Company are commenced under the compromise
                                            or arrangement provisions of the corporation statute pursuant to which the Company is governed,
                                            or the Company enter into an arrangement or compromise with any or all of their respective
                                            creditors pursuant to such provisions or otherwise;

 

		(f)	Companies’
                                            Creditors Arrangement Act. Any proceedings with respect to the Company are commenced
                                            in any jurisdiction under the Companies' Creditors Arrangement Act (Canada) or any
                                            similar legislation; or

 

		(g)	Liquidation.
                                            An order is made, a resolution is passed, or a petition is filed, for the liquidation,
                                            dissolution or winding-up of the Company.

 

Article 6

RIGHTS, REMEDIES AND POWERS

 

		6.1	Upon
                                            Default

 

If
any Event of Default shall occur, the Holder may provide the Company with notice of such Event of Default (the “Default Notice”).
Upon receipt of such notice, the Company shall have the option to cure such Event of Default within thirty (30) days (the “Cure
Period”). If the Event of Default has not been cured by the Company to the reasonable satisfaction of the Holder during the
Cure Period, the Holder shall be entitled to exercise any and all of its rights pursuant to this Debenture, including declaring the Principal
Amount of the Debenture and interest then outstanding on such date and all other amounts outstanding to be due and payable forthwith.

 

		6.2	Waiver

 

The
Holder in its absolute discretion may at any time and from time to time by written notice waive any breach by the Company of any of its
covenants or agreements herein. No failure or delay on the part of the Holder to exercise any right, remedy or power given herein or
by any other existing or future agreement or now or hereafter existing by statute, at law or in equity will operate as a waiver thereof,
nor will any single or partial exercise of any such right, remedy or power preclude any other exercise thereof or the exercise of any
other such right, remedy or power, nor will any waiver by the Holder be deemed to be a waiver of any subsequent, similar or other event.

 

Article 7

OTHER AGREEMENTS

 

		7.1	Withholding
                                            Taxes

 

If
the Company is obliged to withhold any payment hereunder on account of present or future taxes, duties, assessments or other governmental
charges required by law, the Company shall make such withholding or deduction and pay the balance owing to the Holder.

 

		7.2	Amendment
                                            and Waiver

 

Neither
this Debenture nor any provision hereof may be amended, waived, discharged or terminated except by a document in writing executed by
the party against whom enforcement of the amendment, waiver, discharge or termination is sought.

 

     

    A-11 

    

 

		7.3	Notices
                                            and Other Instruments

 

Any
notice, demand or other communication required or permitted to be given to any party hereunder shall be in writing and shall be:

 

		(a)	personally delivered
                                            to such party; or

 

		(b)	except during
                                            a period of strike, lock-out or other postal disruption, sent by double registered mail,
                                            postage prepaid to the address of such party set forth on page one; or

 

		(c)	sent by facsimile
                                            transmission or other means of electronic communication to the address of such party set
                                            forth on page one;

 

and
shall be deemed to have been received by such party on the earliest of the date of delivery under Section 7.3(a), the actual date of
receipt when mailed under Section 7.3(b) and the Business Day following the date of communication under Section 7.3(c). Any party
may give written notice to the other parties of a change of address to some other address, in which event any communication shall thereafter
be given to such party as hereinbefore provided, at the last such changed address of which the party communication has received written
notice.

 

		7.4	Maximum
                                            Rate

 

Notwithstanding
any other provisions of this Debenture or any other agreement, the maximum amount (including interest, fees, bonus and any other consideration)
payable to the Holder in connection with the Debenture and each part thereof shall not exceed the maximum allowable return permitted
under the laws of Ontario and the laws of Canada applicable therein, and the provisions of this Debenture and all other existing and
future agreements are hereby modified to the extent necessary to effect the foregoing.

 

		7.5	Successors
                                            and Assigns

 

This
Debenture shall be binding upon the Company, its successors and permitted assigns, and shall enure to the benefit of the Holder and its
successors and assigns.

 

		7.6	Headings,
                                            etc.

 

The
division of this Debenture into sections and subsections and the insertion of headings are for convenience of reference only and shall
not affect the construction or interpretation hereof.

 

		7.7	Severability

 

The
provisions of this Debenture are intended to be severable. If any provision of this Debenture shall be deemed by any court of competent
jurisdiction or held to be invalid or void or unenforceable in whole or in part in any jurisdiction, such provision shall, as to such
jurisdiction, be ineffective to the extent of such invalidity or unenforceability without in any manner affecting the validity or enforceability
thereof in any other jurisdiction or the remaining provisions hereof in any jurisdiction.

 

		7.8	Holder’s
                                            Rights and Remedies

 

In
addition to the foregoing without limitation: (i) the Holder’s rights and remedies hereunder, shall be cumulative and not exclusive
of any rights or remedies which it would otherwise have; no delay or omission by the Holder in exercising or enforcing any of the Holder’s
rights and remedies hereunder shall operate as, or constitute, a waiver thereof; no waiver by the Holder of any Event of Default shall
operate as a waiver of any other default hereunder; no single or partial exercise of any of the Holder’s rights or remedies hereunder,
and no express or implied agreement or transaction of whatever nature entered into between the Holder and any person, at any time, shall
preclude the other or further exercise of the Holder’s rights and remedies hereunder; no waiver by the Holder of any of the Holder’s
rights and remedies hereunder on any one occasion shall be deemed a waiver on any subsequent occasion, nor shall it be deemed a continuing
waiver; and (ii) the Holder’s rights and remedies hereunder may be exercised at such time or times and in such order of preference
as the Holder may determine.

 

     

    A-12 

    

 

		7.9	Governing
                                            Law

 

This
Debenture shall be governed by and construed in accordance with the laws of the Province of Ontario and of Canada applicable therein
and shall be treated in all respects as a Ontario contract.

 

		7.10	Counterparts

 

This
Agreement may be executed in counterparts and, when each party has executed a counterpart, each of such counterparts shall be deemed
to be an original and all of such counterparts when taken together shall constitute one and the same agreement.

 

		7.11	Electronic
                                            Copies

 

This
Agreement may be executed by the parties and transmitted by e-mail and if so executed and transmitted, this Agreement will be for all
purposes as effective as if the parties had delivered and executed an original Agreement.

 

     

     

    

 

SCHEDULE
b

CONVERSION FORM

 

	TO:	PROMIS NEUROSCIENCES INC. (the “Company”)

 

The
undersigned, being the Holder pursuant to a Debenture dated March 22, 2021 granted by the Company to the undersigned (the “Debenture”),
hereby [irrevocably elects][has been directed at the Company’s election] to convert the Principal Amount of US$_________ under
the Debenture into _________ [Series 1 Shares] [Common Shares] of PROMIS NEUROSCIENCES INC. in accordance with the terms of the
Debenture and directs that the securities issuable and deliverable upon the conversion be issued and delivered to the person indicated
below. (If securities are to be issued in the name of a person other than the Holder, all requisite transfer taxes or fees must be tendered
by the undersigned).

 

		1.	The undersigned
                                            Holder represents, warrants and certifies as follows (only one) of the following must be
                                            checked):

 

 ̈          
A. Regulation S – The undersigned Holder (i) is not in the United States; (ii) is not a “U.S. person” as defined
in Regulation S under the United States Securities Act of 1933, as amended (the “1933 Act”), and is not converting
the Principal Amount (or portion thereof) on behalf of a U.S. person or a person in the United States; and (iii) did not execute or deliver
this notice form in the United States.

 

 ̈          B.
Section 3(a)(9) of the 1933 Act - The undersigned Holder has not been solicited to convert the Principal Amount (or portion thereof)
by any person, or if the undersigned has been solicited to convert the Principal Amount (or portion thereof) the undersigned has confirmed
that no commission or remuneration has been or will be paid or given, directly or indirectly, for soliciting such conversion.

 

 ̈          C.
Rule 506(b) of Regulation D under the 1933 Act - The undersigned Holder has been solicited to convert the Principal Amount (or
portion thereof) but the undersigned has been unable to confirm that no commission or remuneration has been or will be paid or given,
directly or indirectly, for soliciting such conversion. The undersigned (i) is the original purchaser of the Debenture, having participated
in the unregistered private placement offering of Debentures by the Company, (ii) is converting the Principal Amount (or portion thereof)
solely for the undersigned’s own account for investment purposes only, and (iii) the undersigned continues to qualify as an “accredited
investor” (as defined in Rule 501(a) of Regulation D under the 1933 Act).

 

 ̈          D.
Other - The undersigned Holder has delivered to the Company an opinion of counsel reasonably satisfactory to the Company to the
effect that an exemption from the registration requirements of the 1933 Act and applicable state securities laws is available. (Note:
If this box is to be checked, the Holder is encouraged to consult with the Company in advance to determine that the legal opinion tendered
in connection with conversion will be reasonably satisfactory in form and substance to the Company.)

 

		2.	“United
                                            States” and “U.S. person” are as defined in Regulation S under
                                            the 1933 Act.

 

		3.	Certificates
                                            or other instruments representing Series 1 Shares or Common Shares, as applicable, will not
                                            be registered or delivered to an address in the United States unless Box (B) or (C) above
                                            is checked.

 

     

    B-2 

    

 

		4.	If the undersigned
                                            has marked Box (B) and the Debenture bears a U.S. restrictive legend (or is otherwise identified
                                            as a “restricted security” in the Company’s records), or if the undersigned
                                            has marked Box (C) above, the undersigned acknowledges and agrees that:

 

		(a)	the Series
                                            1 Shares or Common Shares, as applicable, will be issued as “restricted securities”
                                            (as defined in Rule 144(a)(3) under the 1933 Act) and that the 1933 Act and the rules of
                                            the United States Securities and Exchange Commission provide in substance that the undersigned
                                            may dispose of such securities only pursuant to an effective registration statement under
                                            the 1933 Act or an exemption or exclusion therefrom;

 

		(b)	if the undersigned
                                            decides to offer, sell or otherwise transfer any of the Series 1 Shares or the Common Shares,
                                            as applicable, the undersigned must not, and will not, offer, sell or otherwise transfer
                                            any of such securities directly or indirectly, unless:

 

		(i)	the sale is
                                            to the Company;

 

		(ii)	the sale
                                            is made outside the United States in a transaction meeting the requirements of Rule 904 of
                                            Regulation S under the 1933 Act and in compliance with applicable local laws and regulations;

 

		(iii)	the sale
                                            is made pursuant to the exemption from the registration requirements under the 1933 Act provided
                                            by Rule 144 thereunder and in accordance with any applicable state securities or “blue
                                            sky” laws; or

 

		(iv)	the securities
                                            are sold in a transaction that does not require registration under the 1933 Act or any applicable
                                            state laws and regulations governing the offer and sale of securities, and it has prior to
                                            such sale furnished to the Company an opinion of counsel reasonably satisfactory to the Company;

 

		(c)	the certificates
                                            or other instruments representing the Series 1 Shares, the Common Shares as well as all certificates
                                            issued in exchange for or in substitution of therefor, until such time as is no longer required
                                            under the applicable requirements of the 1933 Act and applicable state securities laws, will
                                            bear, on the face of such certificate or other instrument, the following legend:

 

THE
SECURITIES REPRESENTED HEREBY HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE
 “1933 ACT”), OR THE LAWS OF ANY STATE OF THE UNITED STATES. THE HOLDER HEREOF, BY PURCHASING SUCH SECURITIES, AGREES FOR
THE BENEFIT OF THE COMPANY THAT SUCH SECURITIES MAY BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED ONLY (A) TO THE COMPANY, (B) OUTSIDE
THE UNITED STATES IN ACCORDANCE WITH RULE 904 OF REGULATION S UNDER THE 1933 ACT AND IN COMPLIANCE WITH APPLICABLE LOCAL LAWS AND REGULATIONS,
(C) IN COMPLIANCE WITH THE EXEMPTION FROM REGISTRATION UNDER THE 1933 ACT PROVIDED BY RULE 144 THEREUNDER, IF AVAILABLE, AND IN ACCORDANCE
WITH APPLICABLE STATE SECURITIES LAWS OR (D) IN ANOTHER TRANSACTION THAT DOES NOT REQUIRE REGISTRATION UNDER THE 1933 ACT OR ANY APPLICABLE
STATE SECURITIES LAWS AND, IN THE CASE OF (C) AND (D) ABOVE, AFTER THE SELLER FURNISHES TO THE COMPANY AN OPINION OF COUNSEL OF RECOGNIZED
STANDING OR OTHER EVIDENCE IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY TO SUCH EFFECT. DELIVERY OF THIS CERTIFICATE MAY NOT CONSTITUTE
 “GOOD DELIVERY” IN SETTLEMENT OF TRANSACTIONS ON STOCK EXCHANGES IN CANADA.”;

 

     

    B-3 

    

 

provided
that if the such securities are being sold outside the United States in compliance with the requirements of Rule 904 of Regulation S,
the legend set forth above may be removed by providing a declaration to the registrar and transfer agent of the Company, as set forth
in Appendix 1 hereto (or in such other form as the Company may prescribe from time to time) and, if requested by the Company or transfer
agent, an opinion of counsel of recognized standing in form and substance satisfactory to the Company to the effect that the transfer
is in compliance with Rule 904; and provided, further, that, if any securities are being sold otherwise than in accordance with Regulation
S and other than to the Company, the legend may be removed by delivery to the registrar and transfer agent and the Company of an opinion
of counsel, of recognized standing reasonably satisfactory to the Company, that such legend is no longer required under applicable requirements
of the 1933 Act or state securities laws;

 

and

 

		(d)	the Company
                                            has no obligation to register any of the Series 1 Shares or the Common Shares or to take
                                            any other action so as to permit sales pursuant to the 1933 Act (including Rule 144 thereunder).

 

		4.	If the undersigned
                                            has marked Box (B) or Box (C) above, the undersigned represents and warrants that the funds
                                            representing the purchase price for the Series 1 Shares or the Common Shares, as applicable,
                                            which will be advanced by the undersigned to the Company will not represent proceeds of crime
                                            for the purposes of the United States Uniting and Strengthening America by Providing Appropriate
                                            Tools Required to Intercept and Obstruct Terrorism Act (the “PATRIOT Act”),
                                            and the undersigned acknowledges that the Company may in the future be required by law to
                                            disclose the undersigned’s name and other information relating to this Warrant Exercise
                                            Form and the undersigned’s subscription hereunder, on a confidential basis, pursuant
                                            to the PATRIOT Act. No portion of the purchase price to be provided by the undersigned (i)
                                            has been or will be derived from or related to any activity that is deemed criminal under
                                            the laws of the United States, or any other jurisdiction, or (ii) is being tendered on behalf
                                            of a person or entity who has not been identified to or by the undersigned, and the undersigned
                                            shall promptly notify the Company if the undersigned discovers that any of such representations
                                            ceases to be true and provide the Company with appropriate information in connection therewith.

 

Dated the _______________
day of _______________, ________.

 

___________________________________________

(Please print full
name)

 

By: ________________________________________ 

(Signature)

 

_____________________________________________

(Print full address,
including postal code)

 

     

    B-4 

    

 

The [Series 1 Shares]
[Common Shares] are to be issued as follows: 

	Registration
    Instructions: Register the [Series 1 Shares] [Common Shares] as set forth below:	Delivery
    Instructions: Deliver the [Series 1 Shares] [Common Shares] as set forth below:
	 	 
	Name	Name
	 	 
	Address,
    including postal code	Address,
    including postal code
	 	 
	Telephone
    Number	 

 

Instructions:

 

		1.	The
                                            registered holder may exercise its right to receive Series 1 Shares/Common Shares by completing
                                            this form and surrendering this form and the Debenture Certificate representing the Debenture
                                            being converted to the head office of the Company at Suite 200, 1920 Yonge Street, Toronto,
                                            Ontario M4S 3E2, Attention: CFO, or such other office as the Company may advise the holder
                                            in writing.

 

		2.	If
                                            the Conversion Form indicates that Series 1 Shares/Common Shares are to be issued to a person
                                            or persons other than the registered holder of the Debenture Certificate, the signature of
                                            such holder of the Conversion Form must be guaranteed by an authorized officer of
                                            a chartered bank, trust company or an investment dealer who is a member of a recognized stock
                                            exchange.

 

		3.	If
                                            the Conversion Form is signed by a trustee, exercise, administrator, curator, guardian, attorney,
                                            officer of a corporation or any person acting in a judiciary or representative capacity,
                                            the certificate must be accompanied by evidence of authority to sign satisfactory to the
                                            Company.

 

     

     

    

 

APPENDIX
 “1”

 

FORM OF DECLARATION
FOR REMOVAL OF LEGEND

 

	TO:	The registrar and transfer agent
                                      for the Company

 

	AND TO:	ProMIS Neurosciences, Inc. (the “Company”)

 

The undersigned
(A) acknowledges that the sale of _______________________ of the Company represented by certificate number _____________ or held in Direct
Registration System (DRS) account number _____________, to which this declaration relates, is being made in reliance on Rule 904 of Regulation
S (“Regulation S”) under the United States Securities Act of 1933, as amended (the “1933 Act”),
and (B) certifies that (1) the undersigned is not (i) an “affiliate” (as that term is defined in Rule 405 under the 1933
Act) of the Company, except solely by virtue of being an officer or director of the Company, (ii) a “distributor” as defined
in Regulation S, or (iii) an affiliate of a distributor; (2) the offer of such securities was not made to a person in the United States
and either (a) at the time the buy order was originated, the buyer was outside the United States, or the seller and any person acting
on its behalf reasonably believed that the buyer was outside the United States, or (b) the transaction was executed on or through the
facilities of a “designated offshore securities market” (such as the TSX Venture Exchange, the Toronto Stock Exchange or
the Canadian Securities Exchange ) and neither the seller nor any person acting on its behalf knows that the transaction has been prearranged
with a buyer in the United States; (3) neither the seller nor any affiliate of the seller nor any person acting on their behalf has engaged
or will engage in any directed selling efforts in the United States in connection with the offer and sale of such securities; (4) the
sale is bona fide and not for the purpose of “washing off” the resale restrictions imposed because the securities are “restricted
securities” (as that term is defined in Rule 144(a)(3) under the 1933 Act); (5) the seller does not intend to replace securities
sold in reliance on Rule 904 of Regulation S with fungible unrestricted securities; and (6) the contemplated sale is not a transaction,
or part of a series of transactions, which, although in technical compliance with Regulation S, is part of a plan or scheme to evade
the registration provisions of the 1933 Act. Terms used herein have the meanings given to them by Regulation S.

 

Dated:   _____________________________

 

		 	X	                  
	 	 	Authorized signatory
	 	 	 
	 	 	 
	 	 	Name of Seller (please print)
	 	 	 
	 	 	 
	 	 	Name of authorized signatory (please print)
	 	 	 
	 	 	 
	 	 	Title of authorized signatory (please print)

 

     

    B.1-2 

    

 

Affirmation By
Seller’s Broker-Dealer

(required for sales in accordance with Section (B)(2)(b) above)

 

We have read the
foregoing representations of our customer, _________________________ (the “Seller”) dated _______________________,
with regard to our sale, for such Seller’s account, of the securities of the Company described therein (the “Securities”).
We have executed sales of the Securities pursuant to Rule 904 of Regulation S under the United States Securities Act of 1933, as amended
(the “1933 Act”), on behalf of the Seller. In that connection, we hereby represent to you as follows:

 

		(1)	no offer to
                                            sell Securities was made to a person in the United States;

 

		(2)	the sale of
                                            the Securities was executed in, on or through the facilities of the Toronto Stock Exchange,
                                            the TSX Venture Exchange, the Canadian Securities Exchange or another designated offshore
                                            securities market (as defined in Rule 902(b) of Regulation S under the 1933 Act), and, to
                                            the best of our knowledge, the sale was not pre-arranged with a buyer in the United States;

 

		(3)	no “directed
                                            selling efforts” were made in the United States by the undersigned, any affiliate of
                                            the undersigned, or any person acting on behalf of the undersigned; and

 

		(4)	we have done
                                            no more than execute the order or orders to sell the Securities as agent for the Seller and
                                            will receive no more than the usual and customary broker’s commission that would be
                                            received by a person executing such transaction as agent.

 

For purposes of
these representations: “affiliate” means a person that directly, or indirectly through one or more intermediaries,
controls, or is controlled by, or is under common control with, the undersigned; “directed selling efforts” means
any activity undertaken for the purpose of, or that could reasonably be expected to have the effect of, conditioning the market in the
United States for the Securities (including, but not be limited to, the solicitation of offers to purchase the Securities from persons
in the United States); and “United States” means the United States of America, its territories or possessions, any
State of the United States, and the District of Columbia.

 

Legal counsel to
the Company shall be entitled to rely upon the representations, warranties and covenants contained herein to the same extent as if this
affirmation had been addressed to them.

 

Date: _______________

 

		 

Name of Firm

 

	By:	 	 
	 	Authorized officerExhibit 10.3.1

 

Certain identified information has been excluded from the exhibit
pursuant to Item 601(a)(6) of Regulation S-K due to personal privacy concerns or pursuant to Item 601(b)(10)(iv) because it is both not
material and is the type of information that the registrant treats as private or confidential. Redacted information is indicated by: [***]

 

 

 

	February 13, 2017  	UBC File: F16-05805

 

VIA EMAIL

 

Dr. Elliot Goldstein

President and CEO

ProMis Neurosciences, Inc.

Suite 200, 1920 Yonge Street

Toronto, ON

M4S 3E2

[***]

 

Dear Dr. Goldstein,

 

	Re:	Collaborative Research Agreement between The University of British Columbia (“UBC”) and Vancouver Coastal Health Authority (“Hospital”) (UBC and Hospital collectively, the “Institution”) and ProMis Neurosciences, Inc. (the “Sponsor”) effective April 1, 2016 (the “Agreement”)

Amendment No. 1

 

The Institution and Sponsor have executed the Agreement and hereby
agree to amend the Agreement as follows:

 

Article 4.1 shall be revised and read as follows: 

 

“4.1
The Parties understand and agree that, subject to Article 4.3, and excluding any intellectual property related costs under Section 7,
the total costs to the Sponsor hereunder will be $[***] (Canadian funds). The Parties acknowledge that any budget categories that may
be described in the Project are estimates only and that changes from category to category may be made at the Institution’s discretion.
The Sponsor will pay to UBC the amounts of the following due dates:

 

	 	1)	Amount already received by UBC	 	$[***]

 

	 	2)	Amount paid in November and December 2017	 	$[***]

 

	 	3)	January 1, 2018	 	$[***]

 

	 	4)	April 1, 2018 - March 31,2019 equal quarterly payments totaling	 	$[***]

 

All other terms and conditions
of the Agreement will remain in full force and effect and will continue for the duration of the Agreement. The Agreement and this Amendment
No. 1 will be read together and constitute one agreement.

 

 

     

     

    

 

This Amendment to the Agreement may be signed in counterparts either
through original copies or by facsimile or electronically each of which will be deemed an original and all of which will constitute the
same instrument.

 

Sincerely,

 

/s/ Jacqueline Lee

Jacqueline Lee

Industry Grants Officer

 

     

     

    

 

SIGNED FOR AND ON BEHALF of

THE UNIVERSITY OF BRITISH COLUMBIA

by its authorized signatory:

 

/s/ Mario Kasapi

	Name:	Mario Kasapi

	Title:	Associate Director, UILO

	Date:	March 16, 2018

 

 

SIGNED FOR AND ON BEHALF of

THE UNIVERSITY OF BRITISH COLUMBIA

by its authorized signatory:

/s/ J. P. Heale

	Name:	Dr. J. P. Heale

	Title:	Managing Director, UILO

	Date:	March 29, 2018

 

 

SIGNED FOR AND ON BEHALF of

VANCOUVER COASTAL HEALTH AUTHORITY

by its authorized signatory:

/s/ W. Robert McMaster

	Name:	Dr. W. Robert McMaster, D. Phil.

	Title:	Vice President Research

	Date:	March 21, 2018

 

SIGNED FOR AND ON BEHALF of

PROMIS NEUROSCIENCES, INC. 

by its authorized signatory:

/s/ Elliot Goldstein

	Name:	Elliot Goldstein, MD

	Title:	President & CEO

	Date:	March 11, 2018

 

 

[signature page]

     

     

    

 

Acknowledged by

/s/ Neil Cashman

Dr. Neil Cashman

Principal Investigator

Department of Neurology

Date: March 11, 2018

 

 

[acknowledgement page]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}]]